ZVRA logo

Zevra Therapeutics (ZVRA) Cash From Financing

Annual CFF

$28.46 M
+$20.11 M+240.80%

31 December 2023

ZVRA Cash From Financing Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly CFF

$64.77 M
+$49.44 M+322.47%

30 September 2024

ZVRA Quarterly CFF Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM CFF

$86.32 M
+$38.51 M+80.54%

30 September 2024

ZVRA TTM CFF Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

ZVRA Cash From Financing Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+240.8%+146.6%+272.0%
3 y3 years+939.2%+3235.0%-25.6%
5 y5 years+1.6%+4388.2%+202.3%

ZVRA Cash From Financing High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 years-74.8%+939.2%at high+1468.4%-25.6%+2591.1%
5 y5 years-74.8%+939.2%-12.8%+1468.4%-25.6%+2591.1%
alltimeall time-74.8%>+9999.0%-12.8%+1468.4%-28.7%+2591.1%

Zevra Therapeutics Cash From Financing History

DateAnnualQuarterlyTTM
Sept 2024
-
$64.77 M(+322.5%)
$86.32 M(+80.5%)
June 2024
-
$15.33 M(+1159.7%)
$47.81 M(+43.0%)
Mar 2024
-
$1.22 M(-75.7%)
$33.43 M(+17.5%)
Dec 2023
$28.46 M(+240.8%)
$5.00 M(-80.9%)
$28.46 M(+22.7%)
Sept 2023
-
$26.26 M(+2661.2%)
$23.20 M(-769.6%)
June 2023
-
$951.00 K(-125.4%)
-$3.46 M(-137.1%)
Mar 2023
-
-$3.75 M(+1359.1%)
$9.34 M(+11.8%)
Dec 2022
$8.35 M(-92.6%)
-$257.00 K(-37.2%)
$8.35 M(+45.5%)
Sept 2022
-
-$409.00 K(-103.0%)
$5.74 M(-29.1%)
June 2022
-
$13.75 M(-390.5%)
$8.09 M(-76.3%)
Mar 2022
-
-$4.73 M(+64.9%)
$34.09 M(-69.9%)
Dec 2021
$113.11 M(+4029.6%)
-
-
Dec 2021
-
-$2.87 M(-247.8%)
$113.11 M(-2.4%)
Sept 2021
-
$1.94 M(-95.1%)
$115.93 M(+1.7%)
June 2021
-
$39.75 M(-46.5%)
$113.94 M(+49.9%)
Mar 2021
-
$74.29 M(<-9900.0%)
$76.01 M(+2675.1%)
Dec 2020
$2.74 M(-44.5%)
-$46.00 K(-9.8%)
$2.74 M(+12.5%)
Sept 2020
-
-$51.00 K(-102.8%)
$2.44 M(-38.0%)
June 2020
-
$1.82 M(+78.0%)
$3.93 M(+19.5%)
Mar 2020
-
$1.02 M(-391.4%)
$3.29 M(-33.4%)
Dec 2019
$4.94 M
-$350.00 K(-124.3%)
$4.94 M(-82.7%)
Sept 2019
-
$1.44 M(+22.7%)
$28.55 M(+2.3%)
DateAnnualQuarterlyTTM
June 2019
-
$1.18 M(-56.0%)
$27.90 M(-0.1%)
Mar 2019
-
$2.67 M(-88.5%)
$27.94 M(-0.3%)
Dec 2018
$28.02 M(<-9900.0%)
$23.27 M(+2852.4%)
$28.02 M(+494.1%)
Sept 2018
-
$788.00 K(-35.3%)
$4.72 M(+21.4%)
June 2018
-
$1.22 M(-55.7%)
$3.89 M(+48.9%)
Mar 2018
-
$2.75 M(-7334.2%)
$2.61 M(-1385.2%)
Dec 2017
-$203.00 K(-100.3%)
-$38.00 K(-9.5%)
-$203.00 K(-67.7%)
Sept 2017
-
-$42.00 K(-30.0%)
-$628.00 K(-75.8%)
June 2017
-
-$60.00 K(-4.8%)
-$2.59 M(+3.2%)
Mar 2017
-
-$63.00 K(-86.4%)
-$2.51 M(-104.1%)
Dec 2016
$61.16 M(-0.5%)
-$463.00 K(-76.9%)
$61.16 M(+1.3%)
Sept 2016
-
-$2.01 M(<-9900.0%)
$60.38 M(-2.4%)
June 2016
-
$20.00 K(-100.0%)
$61.84 M(-48.9%)
Mar 2016
-
$63.61 M(-5205.3%)
$121.05 M(+96.9%)
Dec 2015
$61.47 M(+167.2%)
-$1.25 M(+127.4%)
$61.47 M(+0.9%)
Sept 2015
-
-$548.00 K(-100.9%)
$60.94 M(-0.8%)
June 2015
-
$59.23 M(+1368.2%)
$61.45 M(+127.1%)
Mar 2015
-
$4.03 M(-327.4%)
$27.06 M(+17.6%)
Dec 2014
$23.00 M(+507.3%)
-$1.77 M(+4226.8%)
$23.00 M(-7.2%)
Sept 2014
-
-$41.00 K(-100.2%)
$24.78 M(-0.2%)
June 2014
-
$24.84 M(<-9900.0%)
$24.82 M(<-9900.0%)
Mar 2014
-
-$22.00 K
-$22.00 K
Dec 2013
$3.79 M
-
-

FAQ

  • What is Zevra Therapeutics annual cash flow from financing activities?
  • What is the all time high annual CFF for Zevra Therapeutics?
  • What is Zevra Therapeutics annual CFF year-on-year change?
  • What is Zevra Therapeutics quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Zevra Therapeutics?
  • What is Zevra Therapeutics quarterly CFF year-on-year change?
  • What is Zevra Therapeutics TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Zevra Therapeutics?
  • What is Zevra Therapeutics TTM CFF year-on-year change?

What is Zevra Therapeutics annual cash flow from financing activities?

The current annual CFF of ZVRA is $28.46 M

What is the all time high annual CFF for Zevra Therapeutics?

Zevra Therapeutics all-time high annual cash flow from financing activities is $113.11 M

What is Zevra Therapeutics annual CFF year-on-year change?

Over the past year, ZVRA annual cash flow from financing activities has changed by +$20.11 M (+240.80%)

What is Zevra Therapeutics quarterly cash flow from financing activities?

The current quarterly CFF of ZVRA is $64.77 M

What is the all time high quarterly CFF for Zevra Therapeutics?

Zevra Therapeutics all-time high quarterly cash flow from financing activities is $74.29 M

What is Zevra Therapeutics quarterly CFF year-on-year change?

Over the past year, ZVRA quarterly cash flow from financing activities has changed by +$38.51 M (+146.64%)

What is Zevra Therapeutics TTM cash flow from financing activities?

The current TTM CFF of ZVRA is $86.32 M

What is the all time high TTM CFF for Zevra Therapeutics?

Zevra Therapeutics all-time high TTM cash flow from financing activities is $121.05 M

What is Zevra Therapeutics TTM CFF year-on-year change?

Over the past year, ZVRA TTM cash flow from financing activities has changed by +$63.11 M (+272.00%)